# Subcutaneous Administration of Lisofylline to Healthy Normal Subjects and Subjects With Type 1 Diabetes

> **NCT00896077** · PHASE1,PHASE2 · COMPLETED · sponsor: **DiaKine Therapeutics, Inc.** · enrollment: 8 (actual)

## Conditions studied

- Healthy
- Type 1 Diabetes

## Interventions

- **DRUG:** Lisofylline

## Key facts

- **NCT ID:** NCT00896077
- **Lead sponsor:** DiaKine Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-05
- **Primary completion:** 2009-12
- **Final completion:** 2009-12
- **Target enrollment:** 8 (ACTUAL)
- **Last updated:** 2014-07-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00896077

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00896077, "Subcutaneous Administration of Lisofylline to Healthy Normal Subjects and Subjects With Type 1 Diabetes". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT00896077. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*